Inhibitory effects of bromelain, a cysteine protease derived from pineapple stem (Ananas comosus), on intestinal motility in mice

Neurogastroenterology and Motility

Volumn 23, Issue 8, 2011, Pages

  Borrelli, F ^a   Capasso, R ^a   Severino, B ^a   Fiorino, F ^a   Aviello, G ^a   de Rosa, G ^a   Mazzella, M ^a   Romano, B ^a   Capasso, F ^a   Fasolino, I ^a   Izzo, A A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bromelain; Cysteine protease; Intestinal inflammation; Intestinal motility; Protease activated receptors

Indexed keywords

ACETYLCHOLINE; BARIUM CHLORIDE; BROMELAIN; CROTON OIL; ENMD 1068; FLUORESCENT DYE; GABEXATE; N1 (3 METHYLBUTYRYL) N4 6 AMINOHEXANOYLPIPERAZINE; NEOMYCIN; PIPERAZINE DERIVATIVE; ROLIPRAM; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG POTENCY; ELECTROSTIMULATION; ILEITIS; ILEUM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CONTRACTION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PINEAPPLE; PLANT STEM; PRIORITY JOURNAL; SMALL INTESTINE; SPASMOLYSIS; STREPTOZOCIN DIABETES;

ACETYLCHOLINE; ANANAS; ANIMALS; BARIUM COMPOUNDS; BROMELAINS; CACO-2 CELLS; CHLORIDES; CHOLINERGIC AGONISTS; CROTON OIL; DIABETES MELLITUS, EXPERIMENTAL; ELECTRIC STIMULATION; ENZYME INHIBITORS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; ILEITIS; MALE; MICE; MUSCLE CONTRACTION; PEPTIDES; RECEPTOR, PAR-1; RECEPTOR, PAR-2;

EID: 79960409623     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01735.x     Document Type: Article

References (50)

1. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
2. Otto HH, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev 1997; 97: 133-72.
3. McGrath ME. The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct 1999; 28: 181-204.
4. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988; 22: 191-203.
5. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 2001; 58: 1234-45.
6. Orsini RA. Plastic surgery educational foundation technology assessment committee. bromelain. Plast Reconstr Surg 2006; 118: 1640-4.
7. Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr Med 1995; 113: 303-6.
8. Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung 2000; 50: 728-38.
9. Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Int Med 2000; 132: 680.
10. Mynott TL, Luke RKJ, Chandler DS. Oral administration of protesase inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine. Gut 1996; 38: 28-32.
11. Mynott TL, Guandalini S, Raimondi F, Fasano A. Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Gastroenterology 1997; 113: 175-84.
12. Borrelli F, Capasso F, Capasso R et al. Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation. Br J Pharmacol 2006; 148: 553-60.
13. 2 activation by gabexate mesilate. J Mol Med 1989; 67: 1432-40.
14. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1, 3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 2000; 60: 1425-34.
15. Zizzo MG, Mulè F, Serio R. Activation of P2Y receptors by ATP and by its analogue, ADPbetaS, triggers two calcium signal pathways in the longitudinal muscle of mouse distal colon. Eur J Pharmacol 2008; 595: 84-9.
16. Pol O, Puig MM. Reversal of tolerance to the antitransit effects of morphine during acute intestinal inflammation in mice. Br J Pharmacol 1997; 122: 1216-22.
17. Darmani NA, Izzo AA, Degenhardt B et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 2005; 48: 1154-63.
18. Capasso R, Borrelli F, Cascio MG et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 2008; 155: 681-9.
19. Kelso EB, Lockhart JC, Hembrough T et al. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 2006; 316: 1017-24.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 2002; 104: 183-90.
22. Aviello G, Rowland I, Gill CI et al. Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells. J Cell Mol Med 2010; 14: 2006-14.
23. Jacob C, Yang PC, Darmoul D et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem 2005; 280: 31936-48.
24. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008; 126: 345-52.
25. Chandler DS, Mynott TL. Bromelain protects piglets from diarrhoea caused by oral challenge with K88 positive enterotoxigenic Escherichia coli. Gut 1998; 43: 196-202.
26. Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol 2005; 116: 135-42.
27. Barry GD, Le GT, Fairlie DP. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 2006; 13: 243-65.
28. Traynelis SF, Trejo J. Protease-activated receptor signaling: new roles and regulatory mechanisms. Curr Opin Hematol 2007; 14: 230-5.
29. Sekiguchi F, Takaoka K, Kawabata A. Proteinase-activated receptors in the gastrointestinal system: a functional linkage to prostanoids. Inflammopharmacology 2007; 15: 246-51.
30. Kawabata A, Matsunami M, Sekiguchi F. Gastrointestinal roles for proteinase-activated receptors in health and disease. Br J Pharmacol 2008; 153: 230-40.
31. Cocks TM, Sozzi V, Moffatt JD, Selemidis S. Protease-activated receptors mediate apamin-sensitive relaxation of mouse and guinea pig gastrointestinal smooth muscle. Gastroenterology 1999; 116: 586-92.
32. Kawabata A, Kuroda R, Nishikawa H, Kawai K. Modulation by protease-activated receptors of the rat duodenal motility in vitro: possible mechanisms underlying the evoked contraction and relaxation. Br J Pharmacol 1999; 128: 865-72.
33. Kawabata A, Kuroda R, Nagata N et al. In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. Br J Pharmacol 2001; 133: 1213-8.
34. Mule F, Baffi MC, Cerra MC. Dual effect mediated by protease-activated receptors on the mechanical activity of rat colon. Br J Pharmacol 2002; 136: 367-74.
35. Sekiguchi F, Hasegawa N, Inoshita K et al. Mechanisms for modulation of mouse gastrointestinal motility by proteinase-activated receptor (PAR)-1 and -2 in vitro. Life Sci 2006; 78: 950-7.
36. Lauwers A, Simon S. Pharmaceutical Enzymes. London: Informa Health Care, 1997. pp. 401.
37. Gosalia DN, Salisbury CM, Ellman JA, Diamond SL. High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays. Mol Cell Proteomics 2005; 4: 626-36.
38. Choe Y, Leonetti F, Greenbaum DC et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem 2006; 281: 12824-32.
39. Al-Ani B, Saifeddine M, Kawabata A, Hollenberg MD. Proteinase activated receptor 2: role of extracellular loop 2 for ligand-mediated activation. Br J Pharmacol 1999; 128: 1105-13.
40. Al-Ani B, Wijesuriya SJ, Hollenberg MD. Proteinase-activated receptor 2: differential activation of the receptor by tethered ligand and soluble peptide analogs. J Pharmacol Exp Ther 2002; 302: 1046-54.
41. Lin CB, Chen N, Scarpa R et al. LIGR, a protease-activated receptor-2-derived peptide, enhances skin pigmentation without inducing inflammatory processes. Pigment Cell Melanoma Res 2008; 21: 172-83.
42. Macfarlane SC, Plevin R. Intracellular signalling by the G-protein coupled proteinase-activated receptor (PAR) family. Drug Dev Res 2003; 59: 367-74.
43. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008; 153: 263-82.
44. Kim MH, Choi BH, Jung SR et al. Protease-activated receptor-2 increases exocytosis via multiple signal transduction pathways in pancreatic duct epithelial cells. J Biol Chem 2008; 283: 18711-20.
45. Scott G, Leopardi S, Parker L, Babiarz L, Seiberg M, Han R. The proteinase-activated receptor-2 mediates phagocytosis in a Rho-dependent manner in human keratinocytes. J Invest Dermatol 2003; 121: 529-41.
46. van der Merwe JQ, Hollenberg MD, MacNaughton WK. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: 441-51.
47. Tomkinson A, Raeburn D. The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum. Br J Pharmacol 1996; 118: 2131-9.
48. Bassotti G. Diabetes and gastrointestinal motor activity. Recenti Prog Med 1991; 82: 334-7.
49. Sato K, Ninomiya H, Ohkura S, Ozaki H, Nasu T. Impairment of PAR-2-mediated relaxation system in colonic smooth muscle after intestinal inflammation. Br J Pharmacol 2006; 148: 200-7.
50. Kelso EB, Ferrell WR, Lockhart JC et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum 2007; 56: 765-71.